SCHEMBL6707983

SCHEMBL6707983

Cc1cc(NC(=O)c2c(C3CC3)noc2-c2ccccc2Cl)ccc1C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPAS1 Q99814 3/20 0.48
FLT1 P17948 4/20 0.46
KDR P35968 2/20 0.46
GPBAR1 Q8TDU6 1/20 0.43
RORC P51449 3/20 0.42
LMNA P02545 2/20 0.42
MAPT P10636 2/20 0.42
KDM4E B2RXH2 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
ALDH1A1 P00352 1/20 0.40
TSHR P16473 1/20 0.40
USP2 O75604 1/20 0.40
POLB P06746 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CRACR2A Q9BSW2 1/20 0.40
GLA P06280 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6709120 0.87 FLT1 (0.57) EPAS1FLT1KDRGPBAR1RORC
SCHEMBL6707903 0.85 EPAS1 (0.48) EPAS1GPBAR1RORCLMNAMAPT
SCHEMBL6707226 0.82 EPAS1 (0.43) EPAS1FLT1KDRGPBAR1LMNA
SCHEMBL6707279 0.80 GAA (0.45) EPAS1GPBAR1RORCLMNAMAPT
SCHEMBL6707894 0.80 NPC1 (0.63) LMNAMAPTMEN1KMT2ATDP1
SCHEMBL6707288 0.76 NPC1 (0.48) GPBAR1LMNAMAPTMEN1KMT2A
SCHEMBL6707303 0.74 ALDH1A1 (0.46) EPAS1LMNAMAPTKDM4EMEN1
SCHEMBL6712450 0.74 EPAS1 (0.47) EPAS1FLT1KDRLMNAMAPT
SCHEMBL7465248 0.73 NR3C1 (0.40) EPAS1FLT1KDRGPBAR1RORC
SCHEMBL6709091 0.73 EPAS1 (0.56) EPAS1FLT1KDRGPBAR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040102489-A1 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders SUGEN, INC. 2004-05-27 US disclosed
US-6649635-B2 For therapy of cancer SUGEN, INC. 2003-11-18 US disclosed
US-20020065283-A1 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders MCMAHON GERALD (US) 2002-05-30 US disclosed
EP-1012150-A4 HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS SUGEN INC (US) 2002-05-29 EP disclosed
US-6316479-B1 ANTICANCER AGENTS SUGEN, INC. 2001-11-13 US disclosed
EP-1012150-A1 HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS Sugen, Inc. (US) 2000-06-28 EP disclosed
WO-1998052944-A1 HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS SUGEN, INC. (US) 1998-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020065283-A1 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders ABL1, ERBB2, PRKDC EPAS1 1776/4885FLT1 727/4885KDR 633/4885
US-20040102489-A1 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders ABL1, ERBB2, PRKDC EPAS1 1776/4885FLT1 727/4885KDR 633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.